11/18/2026 | Press release | Distributed by Public on 11/18/2026 13:27
Lake Street Capital Markets Analyst, Daniel Brims, Ph.D., initiated coverage of AbCellera Biologics, Inc. with a BUY rating and price target of $19 (ABCL-$19). AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.